Using insights from Ipsos’ India Oncology Monitor and India Oncology Sales Monitor, together with secondary desk research, this report provides an exhaustive analysis of the Indian oncology landscape, and the environment to consider to ensure pharma brand and company success in this region.
Building on decades of conducting oncology research in China, combined with secondary desk research, this report provides an in-depth look at the forces shaping the evolving China oncology landscape, and the environment to consider to ensure pharma brand and company success in this market.
The wild-type (WT) stage III-IV non-small cell lung cancer (NSCLC) indication presents a key opportunity for treatment innovation. Using real-world clinical insights from Ipsos’ Oncology Monitor, this report provides an invaluable viewpoint for those operating in or entering this dynamic space.
Leveraging insights from Ipsos’ Global Oncology Monitor, these reports provide a granular view of individual tumour treatment landscapes. With key metrics including trended market shares, treatment algorithms, patient and physician profiling – and more – they provide the perfect overview for companies looking to establish, maintain or expand their presence in specific tumour indications.
These dashboards provide a granular view of ovarian, prostate, breast, RCC, H&N and bladder cancer treatment landscapes across KSA, UAE, Kuwait, Oman, and Qatar. Key metrics include market shares, treatment algorithms and patient profiling, providing the perfect overview for strategising in these markets.
The key facts about oncology drug products available in the US, EU4 & UK ‑ all in one interactive interface. This intuitive Tableau-based platform allows you instant access to metrics relevant to your product and your competitors’ products, including brand/molecule name, indication details, approval dates, and more.
Leveraging insights from Ipsos’ Global Oncology Monitor, these reports provide a granular view of oncology biomarker landscapes, their complexities, and their evolution. Align your portfolio with the latest advancements in biomarker-driven therapies to address unmet patient needs – all in the regions where you need visibility.
Market sizing is a crucial exercise to understand the potential reach and value of a drug or treatment. Based on extrapolations of both Ipsos real-world and secondary data, access validated universe sizes across a range of tumour types. Size customer workloads, their management of multiple indications, and annual drug-treated prevalence figures.
Against a comprehensive backdrop of the lung cancer treatment landscape, explore prescriber expectations of the impact of subcutaneous versions of immunotherapies (IOs) in this field. Understand what will drive and hinder adoption – and the potential change in usage of different treatments as a result.
Gain a decisive competitive advantage in the Australian lymphoma market with this report, which offers an unparalleled, real-world analysis of the current DLBCL treatment landscape - including the impact of CAR-T therapies and bispecific antibodies. Equip your team with the foresight needed to anticipate market trends and effectively navigate this evolving therapeutic landscape.
The EHA 2025 Congress showcased significant advancements in the field of multiple myeloma treatment. But which messages resonated most? By examining both clinical and engagement measures at the event, we offer a detailed road-map to optimise promotional conference activity and shape competitive strategies to influence future prescribing behaviour.
Indian and Chinese company partnerships are bringing cheaper immuno-oncology (IO) therapies into the Indian market, increasing access to these treatments while intensifying competitive pressures. Along with key patent expiries, broader shifts in treatment protocols are expected. This report offers practical guidance to navigate and respond to these market changes.
The second-line (2L) maintenance setting in platinum-sensitive ovarian cancer (PSOC) represents a critical juncture in bevacizumab prescribing (reference and biosimilar). This report provides a detailed view of prescribing patterns & physician decision-making rationale, to offer an invaluable vantage point for shaping commercial strategy.
With a healthcare system under mounting financial strain, cost consciousness is now entering clinical decision-making in Japan. This report delivers the strategic intelligence needed to understand how economic pressures are shaping treatment choices—and where opportunities and risks lie.
The Ipsos Immunotherapy Market Sizing Study delivers granular, department-level insights into the utilisation and distribution of leading immunotherapeutic drugs, across multiple tumour types from 2023 through 2025. The report tracks evolving treatment patterns, emerging indications, and the competitive landscape, enabling stakeholders to evaluate both market share and future potential with confidence.